Author(s):
Lakshmi Narasimha Rao Regana, A. Krishna Manjari Pawar
Email(s):
lnrao.reganaqa2012@gmail.com
DOI:
10.52711/2231-5675.2025.00018 
Address:
Lakshmi Narasimha Rao Regana1*, A. Krishna Manjari Pawar2
1Research Scholar, Department of Pharmaceutical Analysis, A.U College of Pharmaceutical Sciences, Andhra University, Visakhapatnam, Andhra Pradesh, India - 530003.
2Associate Professor, Department of Pharmaceutical Analysis, A.U College of Pharmaceutical Sciences, Andhra University, Visakhapatnam, Andhra Pradesh, India - 530003.
*Corresponding Author
Published In:
Volume - 15,
Issue - 2,
Year - 2025
ABSTRACT:
Dexlansoprazole is used in the symptomatic management associated with Gastroesophageal Reflux Disease and Erosive Esophagitis. It is a new generation proton-pump inhibitor. The main aim of this article is to develop and validate an RP-HPLC method for the estimation of Dexlansoprazole in both 20%W/W dual delayed-release pellet and dual delayed-release capsule forms 60 mg. The foundational work facilitated the validation of a newly developed RP-HPLC method for the quantitative of Dexlansoprazole. Method was achieved with Inertsil ODS C18, 100x4.6mm, 5µm at 1.0ml/min flow rate for 10min run time at 285nm. The linearity was achieved in the range of 15-120ppm with R2 value 1.000 and retention time at 4.53min. Accuracy was found to be 98-102% with a precision %RSD of 0.07. This method is designed to be simple, precise, and economical, featuring a shorter run time that makes it ideal for routine quality control applications. The validation was performed in compliance with ICH guidelines, confirming that the established method is reliable for quality control purposes.
Cite this article:
Lakshmi Narasimha Rao Regana, A. Krishna Manjari Pawar. Method Validation for the Quantification of Dexlansoprazole dual-delayed release capsules by RP-HPLC. Asian Journal of Pharmaceutical Analysis. 2025; 15(2):109-5. doi: 10.52711/2231-5675.2025.00018
Cite(Electronic):
Lakshmi Narasimha Rao Regana, A. Krishna Manjari Pawar. Method Validation for the Quantification of Dexlansoprazole dual-delayed release capsules by RP-HPLC. Asian Journal of Pharmaceutical Analysis. 2025; 15(2):109-5. doi: 10.52711/2231-5675.2025.00018 Available on: https://ajpaonline.com/AbstractView.aspx?PID=2025-15-2-7
REFERENCES:
1. Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2005; 54:710–7.
2. Locke GR 3rd, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ 3rd. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology. 1997; 112:1448–56.
3. Nebel OT, Fornes MF, Castell DO. Symptomatic gastroesophageal reflux: incidence and precipitating factors. Am J Dig Dis. 1976; 21:953–6.
4. Hershcovici T, Fass R. Nonerosive reflux disease (NERD)—an update. J Neurogastroenterol Motil. 2010; 16:8–21.
5. Sandler RS, Everhart JE, Donowitz M, Adams E, Cronin K, Goodman C, The burden of selected digestive diseases in the United States. Gastroenterology. 2002; 122:1500–11.
6. Irvine EJ. Quality of life assessment in gastro-oesophageal reflux disease. Gut. 2004; 53 Suppl 4: iv35–9.
7. Bytzer P. Goals of therapy and guidelines for treatment success in symptomatic gastroesophageal reflux disease patients. Am J Gastroenterol. 2003; 98(3 Suppl): S31–9.
8. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology. 1997; 112:1798–810.
9. Fass R, Shapiro M, Dekel R, Sewell J. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease—where next? Aliment Pharmacol Ther. 2005; 22: 79–94.
10. Moore JM, Vaezi MF. Extraesophageal manifestations of gastroesophageal reflux disease: real or imagined? Curr Opin Gastroenterol. 2010; 26: 389–94.
11. Sachs G, Shin JM, Briving C, Wallmark B, Hersey S. The pharmacology of the gastric acid pump: the H+, K+ ATPase. Annu Rev Pharmacol Toxicol. 1995; 35: 277–305.
12. Sachs G, Shin JM, Howden CW. Review article: the clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther. 2006; 23 Suppl 2:2–8.
13. Shin JM, Sachs G. Gastric H, K-ATPase as a drug target. Dig Dis Sci. 2006; 51:823–33.
14. Hunt RH. Review article: the unmet needs in delayed- release proton-pump inhibitor therapy in 2005. Aliment Pharmacol Ther. 2005; 22 Suppl 3:10–19.
15. Hershcovici T, Fass R. Management of gastroesophageal reflux disease that does not respond well to proton pump inhibitors. Curr Opin Gastroenterol. 2010; 26:367–78.
16. Horn JR, Howden CW. Review article: similarities and differences among delayedrelease proton-pump inhibitor formulations. Aliment Pharmacol Ther. 2005; 22 Suppl 3:20–4.
17. Stedman CA, Barclay ML. Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther. 2000; 14: 963–78.
18. Metz DC, Vakily M, Dixit T, Mulford D. Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy. Aliment Pharmacol Ther. 2009; 29: 928–37.
19. Katsuki H, Yagi H, Arimori K, Nakamura C, Nakano M, Katafuchi S, Determination of R (+)- and S(−)-lansoprazole using chiral stationary-phase liquid chromatography and their enantioselective pharmacokinetics in humans. Pharm Res. 1996; 13: 611–5.
20. Vakily M, Zhang W, Wu J, Atkinson SN, Mulford D. Pharmacokinetics and pharmacodynamics of a known active PPI with a novel dual delayed release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials. Curr Med Res Opin. 2009; 25: 627–38.
21. Metz DC, Howden CW, Perez MC, Larsen L, O’Neil J, Atkinson SN. Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis. Aliment Pharmacol Ther. 2009; 29:742–54.
22. Zhang W, Wu J, Atkinson SN. Pharmacokinetics, pharmacodynamics, and safety evaluation of a single and multiple 60 mg, 90 mg, and 120 mg oral doses of modified-release TAK-390 (TAK-390MR) and 30 mg oral doses of lansoprazole in healthy subjects. Gastroenterology. 2007; 132(suppl 52): A487.
23. Vakily M, Wu J, Atkinson SN, Mulford D. Population pharmacokinetics (PK) of TAK- 390MR in subjects with symptomatic non-erosive gastroesophageal reflux disease (GERD). J Clin Pharmacol. 2008; 48:1103.
24. Bell NJ, Burget D, Howden CW, Wilkinson J, Hunt RH. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion. 1992; 51 Suppl 1: 59–67.
25. Wu J, Vakily M, Witt G, Mulford D. TAK-390 MR vs. Lansoprazole (LAN) for maintenance of drug concentration above a threshold which corresponds to higher-time pH > 4. Am J Gastroenterol. 2007; 102(Suppl 2): 124.
26. Lee RD, Vakily M, Mulford D, Wu J, Atkinson SN. Clinical trial: the effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel dual delayed release formulation of a proton pump inhibitor—evidence for dosing flexibility. Aliment Pharmacol Ther. 2009; 29:824–33.
27. Lee RD, Mulford D, Wu J, Atkinson SN. The effect of time-of-day dosing on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR: evidence for dosing flexibility with a dual delayed release proton pump inhibitor. Aliment Pharmacol Ther. 2010; 31:1001–11.
28. Vakily M, Lee RD, Wu J, Gunawardhana L, Mulford D. Drug interaction studies with dexlansoprazole modified release (TAK-390MR), a proton pump inhibitor with a dual delayedrelease formulation: results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies. Clin Drug Investig. 2009; 29:35–50.
29. Vakily M, Zhang W, Wu J, Mulford D. Effect of age and gender on the pharmacokinetics of a single oral dose of TAK-390MR (modified release) [abstract]. Clin Pharmacol Ther. 2008; 83 Suppl 1: S96.
30. Lee RD, Wu J, Vakily M, Mulford D. Effect of hepatic impairment on the pharmacokinetics of TAK-390MR (modified release) [abstract]. Clin Pharmacol Ther. 2008; 2008(83 Suppl 1): S95.
31. Sharma P, Shaheen NJ, Perez MC, Pilmer BL, Lee M, Atkinson SN, . Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation—results from two randomized controlled studies. Aliment Pharmacol Ther. 2009; 29:731–41.
32. Howden CW, Larsen LM, Perez MC, Palmer R, Atkinson SN. Clinical trial: efficacy and safety of dexlansoprazole MR 60 and 90 mg in healed erosive oesophagitis—maintenance of healing and symptom relief. Aliment Pharmacol Ther. 2009; 30:895–907.
33. Fass R, Chey WD, Zakko SF, Andhivarothai N, Palmer RN, Perez MC, Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease. Aliment Pharmacol Ther. 2009; 29:1261–72.
34. Mayer MD, Vakily M, Witt G, Mulford D. The pharmacokinetics of TAK-390MR 60 mg, a dual delayed release formulation of the proton pump inhibitor TAK-390, and lansoprazole 60 mg: a retrospective analysis. Gastroenterology. 2008;134(4 Suppl1).
35. Vakily M, Wu J, Atkinson S. Effect of single oral doses (90 and 300 mg) of TAK-390MR on QT intervals [abstract]. Clin Pharmacol Ther. 2007;81(Suppl1).
36. Kumaraswamy. Gandla, D. Sudheer Kumar, Joru Praveen, Emmadi Suman. RP-HPLC Method Development and Validation for Simultaneous Estimation of Lignocaine Hydrochloride and Clotrimazole Hydrochloride in Ear Drops. Asian J. Pharm. Ana. 2017; 7(3): 163-168. doi: 10.5958/2231-5675.2017.00026.6
37. Kirthi A, Shanmugam R, Mohana Lakshmi S, Ashok Kumar CK, Padmini K, Shanti Prathyusha M, Shilpa V. Analytical Method Development and Validation of a Stability-indicating RP-HPLC Method for the Analysis of Danazol in Pharmaceutical Dosage Form. Asian J. Pharm. Ana. 2016; 6(4): 227-234.
38. D. Samson Israel, Shiny Ganji, B. Vinay Kumar. A Rapid RP HPLC Method Development and Validation for the Analysis of Divalproex in Bulk and Pharmaceutical Dosage Forms. Asian J. Pharm. Ana. 6(1): January- March, 2016; Page 15-22. doi: 10.5958/2231-5675.2016. 00003.X
39. Prashanthi. Y, Tentu Nageswara Rao, Yellapu Srinivas. Method Development and Validation of Alectinib Drug by RP-HPLC in Bulk and Pharmaceutical Dosage Form. Asian J. Pharm. Ana. 2018; 8(4): 186-190. doi: 10.5958/2231-5675.2018.00034.0
40. K. Vijaya Sri, S. Sruthi, M.A. Madhuri. Rapid RP-HPLC Method Development and Validation of Tolvaptan in Bulk and Pharmaceutical Dosage Form for an Internal Standard. Asian J. Pharm. Ana. 2017; 7(1): 36-40. doi: 10.5958/2231-5675.2017.00007.2
41. D. Narmada, P.V. Murali Krishna, Shaik Mohammad Yusuf, B. Ranganayakulu, K. Uday Praveen, P. Raja Abhilash. RP-HPLC method development and validation for estimation of Glibenclamide in tablet dosage form. Asian J. Pharm. Ana. 4(3): July-Sept 2014; Page 125-128.
42. athish Kumar Konidala, Pampana V V Suresh Babu, Ranj, K S D Ranjitha. RP-HPLC Method Development and Validation for the Simultaneous Estimation of Sitagliptin and Simvastatin in Pharmaceutical Formulation. Asian J. Pharm. Ana. 2016; 6(2): 68-76. doi: 10.5958/2231-5675.2016.00011.9
43. Sriharsha J, Srinivasa MM, Bharat KD, Sravan K, Shiva KP, Shirisha A, Pranusha K. Method for development and validation for simultaneous estimation of dexlansoprazole and meloxicam by RP-HPLC. Pharm Anal Acta. 2015; 26:2153-435.
44. N. Vanaja, Ch. Preethi, S.Y. Manjunath, Krishanu Pal. Method Development and Validation for Simultaneous Estimation of Telmisartan and Chlorthalidone by RP-HPLC in Pharmaceutical Dosage Form. Asian J. Pharm. Ana. 5(4): October- December, 2015; Page 171-177. doi: 10.5958/2231-5675.2015.00027.7
45. Mahesh. M, Sridhar Thandra, Shaik Muneer, B. Siva Sai Kiran, H. Mamatha. Method Development and Validation of RP-HPLC Method for the Simultaneous Estimation of Propranolol and Hydralazine in Pharmaceutical Dosage Form. Asian J. Pharm. Ana. 2019; 9(1): 37-42.
46. O. S. S. Chandana, R. Ravichandra Babu. Method Development and Validation of Valsartan and Its Impurities by High Performance Liquid Chromatography. Asian J. Pharm. Ana. 2017; 7(2): 87-92. doi: 10.5958/2231-5675.2017.00015.1
47. Lakshmi Keerthi B, Deepthi R, Srinivasa Rao Y, VaraprasadaRao K. A novel RP-HPLC method development and validation for the estimation of Dexlansoprazole in bulk and extended-release capsules.
48. Bhole RP, Bonde C, Girase G, Gurav S. Stability Indicating Validated Novel RP-HPLC Method for Dexlansoprazole and LC-MS/MS Study of Degradation Product. Palestinian Medical and Pharmaceutical Journal (Pal. Med. Pharm. J.). 2023 Jun 3;9(1):81-106.
49. Balamurugan P, Anver Bash K, Jayachandran JE, Gangrade MA, Parthiban P. A simple RP-HPLC method for simultaneous estimation of organic impurities, enantiomer and assay of dexlansoprazole. International Journal of Pharmacy and Pharmaceutical Sciences. 2015; 7:347-52.
50. Bora R, Narenderan ST, Babu B, Meyyanathan SN, George AJ, Kalaivani M. Sensitive analytical liquid chromatography-tandem mass spectroscopy method for the estimation of dexlansoprazole in pharmaceutical formulations. Journal of Applied Pharmaceutical Science. 2018 Jul 30;8(7):033-6.
51. Sekharan CB, Rao MP, Mahesh M, Chandramouli I, Seemanth J. Determination of the dexlansoprazole in bulk and spiked human plasma by extraction spectrophotometry. International Letters of Chemistry, Physics and Astronomy. 2015 Jan 1; 52:29.
52. ICH guidelines Q2 (R1), Validation of Analytical procedures, Text and Methodology 1995.